Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Lung Cancer

An Introduction to Lung Cancer

Mark CompleteCompleted
BookmarkBookmarked

With #ASCO25 still fresh in our minds, touchONCOLOGY Editorial Board members Dr Fatemeh Ardeshir-Larijani (Emory School of Medicine, Atlanta, GA, USA) and Dr Gabirel Lenz (Hospital Regional Terezinha Gaio Basso, São Miguel Do Oeste, Brazil) reflect on their top key breakthroughs and take-aways from the conference in non-small cell lung cancer (NSCLC).

15 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Expert insights on the practical application of immunotherapy in early-stage NSCLC

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more supportive healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

13 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT FOCUS
Dr Christine Bestvina

Watch an expert discuss the key clinical questions surrounding currently approved RET inhibitors in NSCLC.

Mark CompleteCompleted
BookmarkBookmarked

This year, we are celebrating our inaugural touchONCOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform oncology and haematology in the years to come.

Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, ...

54 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchSYMPOSIUM
Prof. Marina Garassino, Prof. Jaruskha Naidoo, Prof. David Planchard

In this symposium, three lung cancer specialists share their insights on TROP2-targeted ADCs in NSCLC

Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, ...

Mark CompleteCompleted
BookmarkBookmarked

Dr Elene Mariamidze (Todua Clinic, Tbilisi) has built a career shaped by diverse mentorship and a commitment to patient-centered oncology. She reflects on invaluable lessons from global experts, the future of oncology, and practical advice for aspiring oncologists entering this challenging yet rewarding field.

46 mins
Sponsored Content
touchFEATURE
For HCPs in: Global
This activity is funded by AstraZeneca for HCPs only

In this short series of engaging videos, four leading oncology experts discuss current unmet needs in EGFRm NSCLC, the importance of MET diagnostic testing, and treatment options for non-oncogene-addicted NSCLC.

55 mins
Sponsored Content

In this activity, watch leading oncology experts discuss recent consensus statements from near-global groups on the diagnosis, testing, and management of METex14 skipping NSCLC.

Mark CompleteCompleted
BookmarkBookmarked

The US Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) for zongertinib (BI 1810631), a treatment for adults with advanced non-small cell lung cancer (NSCLC) characterized by HER2 (ERBB2) mutations who have undergone prior ...

Mark CompleteCompleted
BookmarkBookmarked

Our Editorial Board supports our mission to advance medical knowledge and practice by ensuring the integrity, relevance and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of ...

29 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchEXPERT OPINIONS
Dr David S Hong, Dr Eileen M O’Reilly, Dr Rebecca S Heist

Experts discuss the role of RAS mutations in solid tumours and how they may be targeted to improve outcomes.

20 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked

Watch a lung cancer expert discuss the latest data for ADCs in NSCLC and their implications for clinical practice.

Mark CompleteCompleted
BookmarkBookmarked

It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies ...

Mark CompleteCompleted
BookmarkBookmarked
Asrar A Alahmadi, Logan Roof, Claire Verschraegen

Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...

Load More...
Close Popup